hgf  (Elabscience Biotechnology)

Journal: International Dental Journal

Article Title: Developing a Silver Nanocomposite With Quorum-Quenching Enzyme Ag-Est816 to Prevent Periodontitis

doi: 10.1016/j.identj.2026.109481

Figure Lengend Snippet: CCK-8 value of HGFs of Ag-Est816 and PBS at Day 1, 3 and 7. Ag-Est816, nanocomposite of silver nanoparticles and N -acyl-homoserine lactone-lactonase Est816; CCK-8, cell counting Kit-8; HGFs, human gingival fibroblasts; PBS, phosphate-buffered saline (control), ns, P > .05).

Article Snippet: The Est816 was prepared and purified according to our established protocols, and its molecular mass was confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis., , Human gingival fibroblasts (HGFs) (HGF-1, ATCC CRL-2014) were used in the following experiments.

Techniques: CCK-8 Assay, Cell Counting, Saline, Control

Journal: International Dental Journal

Article Title: Developing a Silver Nanocomposite With Quorum-Quenching Enzyme Ag-Est816 to Prevent Periodontitis

doi: 10.1016/j.identj.2026.109481

Figure Lengend Snippet: Cytocompatibility of HGFs treated with Ag-Est816 nanocomposite and PBS (control) at Day 1, 3 and 7. Ag-Est816, nanocomposite of silver nanoparticles and N -acyl-homoserine lactone-lactonase Est816; PBS, Phosphate-buffered Saline (Control). Immunofluorescence staining: F‑actin labelled the cytoskeleton in red, DAPI labelled nuclei in blue.

Article Snippet: The Est816 was prepared and purified according to our established protocols, and its molecular mass was confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis., , Human gingival fibroblasts (HGFs) (HGF-1, ATCC CRL-2014) were used in the following experiments.

Techniques: Control, Saline, Immunofluorescence, Staining

Journal: Bioactive Materials

Article Title: Mesenchymal stromal cells-loaded 3D radially aligned composite scaffold with potentiated paracrine signaling for sequential bone regeneration

doi: 10.1016/j.bioactmat.2026.02.059

Figure Lengend Snippet: Temporal analysis of the BMSC paracrine profile on different scaffolds. (A) Confocal microscopy images from Live/Dead fluorescence staining of BMSCs encapsulated within the PCL/HAp-GelMA/BMSCs scaffold after 1, 3, 5, and 14 d of 3D culture (live cells, green; dead cells, red). (B) The concentrations of key paracrine factors (TGF-β, PGE2, VEGF, HGF, and BMP-2) from BMSCs cultured in different scaffolds, quantified from culture supernatants at day 3 and day 7. (C) Corresponding relative mRNA expression levels of TGFB1, PTGS2, VEGFA, HGF, and BMP-2 in BMSCs at day 3 and day 7, as determined by qPCR analysis. Data are presented as mean ± SD (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant.

Article Snippet: ELISA kits for PGE2 (Cat. No. E-EL-0034), TGF-β (Cat. No. E-EL-0162), VEGF (Cat. No. E-EL-R2603), and HGF (Cat. No. E-EL-R0496) were purchased from Elabscience (Wuhan, China).

Techniques: Confocal Microscopy, Fluorescence, Staining, Cell Culture, Expressing

Journal: medRxiv

Article Title: A liver-heart endocrine axis revealed by systems genetics and mediated by hepatocyte growth factor activator

doi: 10.64898/2026.05.05.26352474

Figure Lengend Snippet: (a) Schematic illustrating the analytical framework used to identify liver–heart crosstalk mediators by integrating bulk RNA sequencing data and cross-tissue transcript correlation analysis. Liver–heart crosstalk scores (S sec ) calculated using QENIE, which quantifies the aggregate correlation (biweight midcorrelation) between the expression of a liver-expressed secreted protein gene and the global cardiac transcriptome, identify Hgfac as a candidate liver-derived mediator. ( b ) Expression correlation analysis using GD-CAT to assess data from the Genotype-Tissue Expression (GTEx) project where tissues were assessed with the expression of HGFAC in liver tissue with a qvalue cutoff of q<0.1. All 310 individuals (across both sexes) were used, and FDR adjustments were calculated using a Benjamini-Hochberg method. ( c ) List of disease and traits associated with HGFAC and HGF genetic variants in humans using PhenoScanner V2.

Article Snippet: Expression across tissues from The Human Protein Atlas for ( a and b ) HGFAC , ( c ) HGF , and ( d ) MET reported as normalized protein-coding transcripts per million (nTPM). medrxiv;2026.05.05.26352474v1/FIGS2 F6 figs2 Extended Data Fig. 2.

Techniques: RNA Sequencing, Expressing, Derivative Assay

Journal: medRxiv

Article Title: A liver-heart endocrine axis revealed by systems genetics and mediated by hepatocyte growth factor activator

doi: 10.64898/2026.05.05.26352474

Figure Lengend Snippet: Levels of ( a ) HGFAC and ( b ) HGF were measured in the UK Biobank cohort at baseline (n = 37,055) on the Olink platform. Cox proportional hazards regression models were used to evaluate quintiles of serum HGFAC and HGF protein levels with cumulative incidence of HF with adjustment for age, sex, self-reported ethnicity, BMI, LDL, HDL, systolic blood pressure, diabetes, lipid-lowering medications, and anti-hypertension medications. Forest plots indicating the odds of HFpEF in Cleveland cohort (n = 406) by ( c ) HGFAC and ( d ) HGF tertiles from plasma samples assayed by ELISA. Multivariable logistic regression model for odds ratio included adjustments for age, sex, current smoking, SBP, DM, dyslipidemia (high-density lipoprotein cholesterol ≤40 mg/dL, or low-density lipoprotein cholesterol≥130 mg/dL or triglycerides≥150 mg/dL), symbols represent odds ratios, and the 95% confidence interval is indicated by line length.

Article Snippet: Expression across tissues from The Human Protein Atlas for ( a and b ) HGFAC , ( c ) HGF , and ( d ) MET reported as normalized protein-coding transcripts per million (nTPM). medrxiv;2026.05.05.26352474v1/FIGS2 F6 figs2 Extended Data Fig. 2.

Techniques: Medications, Clinical Proteomics, Enzyme-linked Immunosorbent Assay